Eleusis SPAC
Exploring Psychedelics Beyond Psychiatry - Eleusis Drug Discovery Platform
Discovery Mission
Identify new indications beyond psychiatry
and expand new chemistry library
Ubiquitous Expression
and Key Modulatory Role
eleusis
Receptor target (5-HT2A) is
highly expressed throughout
the periphery and CNS on
key cell types that modulate
immune, metabolic, and
synaptic function ¹,2
Advance a topically delivered therapy
for ocular disease
Validated Target in
Multiple Therapeutic Areas
Translation Mission
Psychedelics have been
validated in multiple
translational models and
across a broad range of
therapeutic areas beyond
psychiatry¹,3
Clarifying MoA to Guide
Discovery
■
■
Studying effects on innate and
adaptive immune function, cell
viability, and metabolic function
Medicinal chemistry effort focused
harnessing these effects and
identifying new drug candidates
Source: 1) Flanagan, T. W., et al. (2018). Psychedelics as anti-inflammatory agents. International Review of Psychiatry, 1-13; 2) Nichols, D. E et al. (2016). Psychedelics as Medicines: An Emerging New Paradigm. Clinical
Pharmacology and Therapeutics 3) Eleusis sponsored studies and sponsored university research program
20View entire presentation